Showing posts with label pap smear. Show all posts
Showing posts with label pap smear. Show all posts

Monday, October 1, 2018

ACOG updates its Recommendations for Well-Woman Care


The American College of Obstetrics and Gynecology (ACOG) recently updated its guidance on well- women care with an emphasis on the vital role an Ob/Gyn plays in maintaining the overall health of women from menarche to menopause and beyond.

The update coincides with the release of ACOG-led Women’s Preventive Services Initiative’s (WPSI) new Well-Woman Chart. The guidance titled “Well Women Visit” was published in the October issue of Obstetrics and Gynecology and replaces the earlier opinion released in August 2012.

The new guidance emphasizes the performance of physical examination (breast and pelvic examination) when indicated by age-group, history or symptoms. The committee also identified the Well-Woman Chart from the WPSI, U.S. Preventive Services Task Force (USPSTF) and Bright Futures, as an important tool to identify the different components of the comprehensive preventive services offered.

Looking at the chart, the Ob/Gyn or other women’s health care providers can prioritize the component for a timely and detailed approach for continuous preventive care throughout the entire lifespan. The Well-Woman Chart provides a list of all the preventive services recommendations for women from the WPSI, US Preventive Services Task Force, and Bright Futures.

The services are advised according to age groups and start at age 13 and end at 75 years with services categorized into general health, infectious disease, and cancer. The chart also has separate services listed for pregnancy and postpartum period.

Much has changed in the last 10 years to shift the focus of patients and practitioner when it comes to yearly well-women visit. The decade has seen a change in the recommendation about the frequency of yearly pap smears, growing popularity of long-acting reversible contraceptive methods and the mandate of performing the pelvic examination in every visit.

The recommendations also recognize that it may not be possible for the patient to complete all the services with one health care provider; hence a team-based approach will facilitate the completion of the services.

The practitioner should begin by a comprehensive medical, family, and reproductive history to individualize physical examination, immunization, and risk assessment. 

The decision to perform a breast and pelvic examination at each visit should be based on detailed family history, reproductive history, and shared decision making. The ACOG recent guidance recommends that pelvic and breast examinations be performed when indicated by medical history or symptoms.

The provider should also counsel the women about essential lifestyle choices and behaviors that have a detrimental effect on women’s’ health like smoking, alcohol, poor diet, and lack of exercise.  These factors also predispose women to high risk for cardiovascular diseases, gynecological cancers, and type 2 diabetes.

All women should be screened for obesity and overweight, and the opportunity should not be lost for counseling the women about maintaining ideal weight and exercising regularly. 

The provider should also discuss with reproductive age women about their reproductive life plan to ensure that all the immunizations are timely complete if planning a pregnancy. Matters like infertility and contraception should also be discussed as appropriate.

The authors further write that discussion about bone health, vulvovaginal symptoms, and sexual health are seldom done during the well-woman visit. The recommendations encourage discussing these issues based on the woman’s phase of life.

In all, an obstetrician and gynecologist should play a crucial role in providing primary and preventive care services to women of all ages.

Christopher Zahn, MD, ACOG vice president of Practice Activities, said in an ACOG news release, “Increasingly, women look to their ob-gyn for both reproductive and primary health care, which creates an exciting opportunity for ob-gyns to build even deeper and longer lasting relationships with our patients,” said Zahn.

“An ob-gyn may care for a patient as an adolescent, through her reproductive years, and as she experiences menopause and beyond. These resources are here to ensure that these ongoing updates to well-woman recommendations are manageable and positive for women’s health care providers and the women who are in their care,” he added further.



Monday, February 12, 2018

Unusually high prevalence of Trichomonas vaginalis observed in pre-/perimenopausal women


Substantial population of older women harbor Trichomonas vaginalis without being aware of the infection reports the results of retrospective observational study to be published in the American Journal of Obstetrics & Gynecology.

As women progress into pre- and perimenopausal years, the prevalence of T. vaginalis increases, with the highest incidence found around 47 to 53 years of age, while the prevalence of Chlamydia trachomatis peaks around 10 years to 27 years and then slowly declined.

Quantitative real-time polymerase chain reactions were used in analyzing 1,554,966 and 1,999,077 cervicovaginal samples collected during gynecological examinations from women aged 10 to 79 years  for presence of T. vaginalis and C trachomatis, respectively. 

It was seen that T. vaginalis has a bimodal distribution with the first peak at age 22 years (4.1%) and another at age 48 (5.8%).  The prevalence of T. vaginalis also remained high at 4% in women aged 54 to 60 years.

A state-wide analysis showed that Mississippi (9.0%) has the highest prevalence for T. vaginalis while C.trachomatis was most common in Maine(6.4%).

This study is important because T. vaginalis is most common non-viral sexually transmitted disease but the physicians are not required to report the cases. Hence, not much is known about it distribution and prevalence.  

In about 1.5% T. vaginalis positive specimens were associated with ntr6TV polymorphism, but it was not related to the age distribution pattern seen in the study.

The authors concluded that it may be good idea to test older women for T. vaginalis infection, who are least suspected of harboring a sexually transmitted infection.


Thursday, October 6, 2016

Cervical cancer screening interval can be extended beyond five years in HPV negative women.

 Clinical pearls:

  • Primary HPV testing provides better protection against cervical cancer than cytology screening tests.
  • HPV negative women who are at-least 40 years of age have a very low risk of cervical pathology and the screening interval can be increased to 10 years in Netherlands. All other women continued to be screened every 5 years.
  • HPV positive women, who are triage negative, or negative for HPV 16/18 genotyping have a very high risk of developing CIN3+ or cervical cancer, and the screening intervals cannot be extended beyond 5 years.
  • The use of HPV testing and age of the patient is the first step towards risk based screening.


Randomized control trials in the past have shown that HPV based screening provides a better protection against CIN3 than only cytology based screening.  Dutch researchers have reported the results of large population based study that confirms the findings from earlier studies. They suggest that cervical cancer screening interval for those women who test negative for HPV and are older (40+ years) can be safely extended from 5 to 10 years. All other women can get the screening at 5 years’ interval.

Separate screening intervals are defined for women who are HPV negative and those who were initially HPV positive but subsequent HPV negative after the triage test, because they face different risks for CIN3.[1]

Many countries (Australia, Italy, Netherlands, New Zealand, Sweden, and the UK) around the world have adopted or recommended HPV screening as the primary screening procedure and US still combines it with cytology.  When advocating for change in policies, the risk of interval cancer should also be taken into account. So longitudinal studies are required to document the incidence of long term cervical cancer.

New data analysis from the Netherlands was published in British Medical Journal, published 04 October 2016, suggest that the interval for cervical screening for HPV-negative individuals, older than 40 years) could be extended from 5 years to 10 years; all other women should continue to be screened every 5 years.[2]

The study is a population based 14 years follow up of cohorts from earlier POBASCAM randomized trial. (population based screening study Amsterdam). The follow up of 14 years comprised of three screening rounds first at baseline, then at five years and 10 years.

A total of 44 938 women aged between 29 and 61 were enrolled, 22 420 were randomized to the intervention group (cytology and HPV co-testing) and 22 518 to the control group (cytology with blinded HPV testing).

Follow up data was collected till year 2013, till that point of time every woman had the opportunity to undergo three rounds of 5-year screening.

Study results showed that the cumulative incidence of cervical cancer and CIN3+ among HPV negative women in the intervention group was similar to negative cytology in control group after two rounds of screening.

Cervical cancer and CIN risk ratios were .97 and .82 respectively.

In women with HPV negative and in the age range of 40+ years, the CIN3+ incidence was 72% lower as compared to younger women. (< .001). 

Women who were   HPV-positive but had negative results on HPV 16/18 genotyping and negative results on baseline and repeat cytology testing had 10.4 times the cumulative risk of developing CIN3 than HPV-negative women.

Similarly, HPV-positive women with negative cytology triage had 11.9-fold higher risk for developing cervical cancer than among HPV-negative women. After adding HPV 16/18 genotyping or repeat cytology as a triage test, only one cancer case was observed.

The study results show that HPV based screening programme provides a better protection as compared to cytology results. Long term incidences of cervical cancer and CIN3+ were low among HPV negative women in this study cohort, and supports an extension of the cervical screening interval beyond five years for women aged 40 years and older. 

HPV positive women with negative repeat cytology, HPV16/18 genotyping, and/or repeat cytology have at least a fivefold higher risk of CIN3+ than HPV negative women, indicating that HPV based screening programmes with long intervals (>five years) should be implemented with risk stratification according to the age of the patients. 





[1] Bulkmans NWJ, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet2007;370:1764-72.doi:10.1016/S0140-6736(07)61450-0 pmid:17919718.
[2] http://www.bmj.com/content/355/bmj.i4924

Friday, January 1, 2016

Few decisive articles in gynecology from 2015



Medication approved for low sexual desire in women.

Flibanserin is the first and currently only drug approved by the US Food and Drug Administration (FDA) for female sexual dysfunction. The U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is hailed by many as “Female Viagra”, but the daily dosing, severe adverse reaction when combined with alcohol, somnolence and dizziness limits its use. Also the daily dosing will only result in   modest increase in sexually satisfying event and sexual desire.


New guidelines from Bethesda for cervical screening cytology reporting.

The past decade has witnessed several changes in the realm of cervical cancer screening, prevention, and management. A new category was created as ‘ASC-H ‘which includes those Low-grade squamous intraepithelial lesion (LSIL) specimens that contain a few cells that are suspicious for but not diagnostic of high-grade squamous intraepithelial lesions (HSIL). More testing is recommended in the form of colposcopy and biopsy.
The Bethesda System 2001 for reporting cervical cytology recommends reporting benign-appearing, exfoliated endometrial cells (BEC) in women aged 40 years or older. The 2014 guidelines advocate it’s reporting only in women ≥45 years as finding of BEC was not found to be effective for predicting endometrial hyperplasia or carcinoma in women aged 40-45 yrs. 



CDC updates the guidelines on the management of sexually transmitted infections in June 2015. 

 

These updated guidelines discuss:




  • Screening recommendations for gonorrhea and chlamydia;
  • Nucleic acid amplification tests for diagnosing trichomoniasis;
  • Updated treatment for chlamydia during pregnancy;
  • Updated human papillomavirus (HPV) vaccine recommendations;
  • Alternative treatment options for genital warts;
  • The role of Mycoplasma genitalium in urethritis and cervicitis;
  • Information on the clinical care of transgender men and women.
  • Annual testing for hepatitis C in persons with HIV-infected men who have sex with men and T. vaginalis testing for HIV-infected women annually and when pregnant;
  • Updated recommendations for diagnostic evaluation of urethritis;
  • T. vaginalis retesting in women to detect repeat infection after 7 days of treatment.

Timing is important in Menopausal Hormone Therapy (MHT).


The use of MHT has been a subject of debate two decades.  However studies in 2015 and an updated version of Cochrane review that was published in 2013 lend support to the ‘timing hypothesis’, which posits that cardiovascular benefit may be derived when ET or HT is used close to the onset of menopause. It is seen in recent studies that menopausal hormone therapy (MHT) in the early menopausal years (<10 years from menopause) may not be associated with excess cardiovascular risk when compared with use in the later menopausal years.
This hypothesis was further supported by a meta-analysis of 19 trials of oral HT (which included the women’s health initiative) leading to a combined total of 40,410 post-menopausal women. These women had a lower risk of coronary heart disease (CHD) compared with placebo and a lower mortality rate. The relationship of duration of therapy to cardiovascular outcomes awaits further study. Furthermore, additional studies on progesterone versus synthetic progestins are needed.

Topical steroids confer protection against Vulvar carcinoma in women with Vulvar Lichen Sclerosus(VLS).



A prospective longitudinal cohort study conducted by a private dermatologist and gynecologist included 507 women with histologically proven VLS. The study objective was long-term preventive topical corticosteroid (TCS) treatment of VLS, with a target outcome of induction and maintenance of normal skin texture and color, reduces the risk of vulvar carcinoma, relieves symptoms, improves function, and preserves vulvar architecture, and to evaluate the adverse effects of treatment.
It was seen that women who was compliant with the treatment had a better chance of near normal cosmetic appearance, decreased risk of vulvar carcinoma. The adverse effects of corticosteroids were minimal.

References:





http://www.ncbi.nlm.nih.gov/pubmed?term=25754617